Latest Headlines

Agricultural trading platform plans to disrupt its chosen market after a recent fund raising.

Monadelphous has been engaged to deliver construction services at Fortescue Metals Group’s new magnetite project as part of a suite of new contracts and extensions worth $150 million.

Melbourne-based Victory Offices has 1,100sqm of co-working space Perth’s Exchange Tower.

Lendlease and Realside are closing in on a $340 million deal to purchase the former Bond Tower from Brookfield.

Former British Airways chief executive Rod Eddington has been appointed to the advisory board of Squadron Energy, a subsidiary of Andrew and Nicola Forrest's company Tattarang.

NRW boss Jules Pemberton says the business is in the process of redeploying equipment and personnel after the sudden closure of Gascoyne’s Dalgaranga operation yesterday.

The lithium sector has a major role to play in broadening the appeal of Western Australia’s resources offerings, a recent RSM forum has heard.

Specialist telecommunications business AVI has developed its products to meet a rapidly changing tech environment.

National Australia Bank has delivered an 8.3 per cent lift in annual earnings after a strong year and says it's well positioned for fiscal 2023.

Forrest’s battle to save the seas from mining

BGC was the second major residential builder this week to paint a picture of how dire the sector is, posting a big annual loss.

Western Power will have $18.5 million docked from its revenue by the Economic Regulation Authority for falling below service standard targets.

More than 600 hectares of land in North Ellenbrook has recently been assessed as potential future development plans loom for the area.

Senior journalist Claire Tyrrell talks about highlights from her recent conversation with Primewest's founders following the group's rebranding as Centuria.

Italian contractor Webuild has struck a deal to buy engineering company Clough with a cash payment of just $500,000 and cancellation of a big inter-company loan.

Copenhagen, Glasgow, Paris; now there’s a move to add Perth to the list of host cities for the huge UN COP international climate conference.

The big banks and lithium miners helped the ASX200 jump another 0.36 per cent on Tuesday, despite sharp losses by the energy sector and James Hardie Industries.

Two South32 employees have been killed and a contractor seriously injured at the miner’s Mozal aluminium smelter in Mozambique.

Fast-growing Perth business Wizard Pharmacy has engaged EY to find a private investor to support its expansion to 100 stores across Australia.

Northern Star Resources and SRG Global are among the businesses moving into 500 Hay Street, as its developer allays fears about the building's structural integrity.

Perth dealmaker Michael Ashforth is making a return to investment banking, seven years after he retired from Macquarie Capital to work for ‘rich lister’ Angela Bennett.

Gascoyne Resources has suspended mining at its Murchison flagship and will begin demobilising its workforce after succumbing to ballooning costs and labour shortages.

The Primewest brand may be gone but its three founders are still doing deals.

Three Perth mates have raised US$5m for their US-based shopping startup.

The federal government has proposed six steps to improve the procurement process, which is too long in an increasingly dynamic environment.

Super tax concessions are in the Albanese government's line of sight as it looks for opportunities to boost revenue and repair the budget bottom line.

Snowy 2.0 hydro caught in Clough cash crunch

The sale of WA's TAB has been shelved after the preferred bidder and the state government failed to agree to terms.

Qteq executive chair Simon Ashton is suing his former WellDog colleagues, claiming they contributed to the company's insolvency by failing to repay millions of dollars.

Senior editor Mark Pownall explains what makes a commercially successful biotechnology business in WA.

The Australian share market has started the week up 0.6 per cent, with the mining sector enjoying its best performance in a month amid China reopening rumours.

Artrya’s coronary diagnostic product has been given regulatory approval for use in the UK after being knocked back by the US Food and Drug Administration five months ago.